Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease

Author:

Batson Jennifer12,Toop Hamish D.13ORCID,Redondo Clara4,Babaei-Jadidi Roya2,Chaikuad Apirat45,Wearmouth Stephen F.3,Gibbons Brian1,Allen Claire2,Tallant Cynthia4,Zhang Jingxue3,Du Chunyun6,Hancox Jules C.6,Hawtrey Tom3,Da Rocha Joana3,Griffith Renate7ORCID,Knapp Stefan45,Bates David O.12,Morris Jonathan C.3ORCID

Affiliation:

1. Exonate Ltd, Unit 23, Cambridge Science Park, Cambridge, United Kingdom

2. Cancer Biology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Queen’s Medical Centre, Nottingham NG2 7UH, United Kingdom

3. School of Chemistry, UNSW Australia, Sydney, Australia

4. Structural Genomic Consortium, University of Oxford, Old Road Campus, Oxford OX3 7DQ, United Kingdom

5. Institute for Pharmaceutical Chemistry and Buchmann Institute for Life Sciences, Johann Wolfgang Goethe-University, D-60438, Frankfurt am Main, Germany

6. School of Physiology and Pharmacology and Neuroscience, University of Bristol, BS8 1TD, Bristol, United Kingdom

7. School of Medical Sciences, UNSW Australia, Sydney, Australia

Funder

Medical Research Council

Heart Research UK

Exonate Ltd

UNSW Goldstar Award

University of Nottingham HERMES Fellowship

EU Network PRIMES

SGC

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3